1. Covid-19: South Africa pauses use of Oxford vaccine after study casts doubt on efficacy against variant
2. AstraZeneca. Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern. Jul 2021. https://www.astrazeneca.com/media-centre/press- releases/2021/vaxzevria-is-highly-effective-after-one-dose-against-severe-disease-or-hospitalisation-caused-by-beta-and-delta-variants-of-concern.html.
3. Burger R, Maughan-Brown B, Köhler T, English R, Tameris M. A shot in the arm for South Africa—increased openness to accepting a COVID-1789 vaccine: Evidence from NIDS-CRAM Waves 4 and 5. National Income Dynamics Study (NIDS)—Coronavirus Rapid Mobile Survey (CRAM). 8 Jul 2021. https://cramsurvey.org/wp-content/uploads/2021/07/2.-Burger-R.-Maughan-Brown-M.-Kohler-T.-English-R.-_-Tameris-M.-2021-Increased-openness-to-accepting-a-COVID-19-vaccine-is-a-shot-in-the-arm-for-South-Africa-Evidence-from-the-NIDS-CRAM-Wave-5-Survey.pdf.
4. AfroBarometer. South Africans unsure of safety of COVID-19 vaccines; many unlikely to get vaccinated. https://afrobarometer.org/press/south-africans-unsure-safety-covid-19-vaccines-many-unlikely-get-vaccinated.
5. Davies M, Furneaux R. Pfizer backs down over “unreasonable” terms in South Africa vaccine deal. Mail & Guardian 2021 Apr 19. https://mg.co.za/news/2021-04-19-pfizer-backs-down-over-unreasonable-terms-in-south-africa-vaccine-deal.